Intermittent androgen deprivation therapy (IADT) with a short or very short off cycle combined with 5α-reductase inhibition might improve survival in patients with prostate cancer, say researchers. Previous work had shown that IADT combined with the 5α-reductase inhibitor finasteride prolonged survival in animals with androgen-sensitive prostate tumours when off-cycle duration was fixed at 10–14 days, but that tumour growth resumed after several days. Pascal et al. used the LNCaP xenograft tumour model to show that use of IADT with 4-day off-cycles combined with the 5α-reductase inhibitor dutasteride inhibited tumour regrowth and increased survival.
References
Pascal, L. E. et al. 5α-reductase inhibition coupled with short off cylces increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J. Urol. 10.1016/j.uro.2014.10.101
Rights and permissions
About this article
Cite this article
IADT combined with 5α-reductase inhibition. Nat Rev Urol 12, 4 (2015). https://doi.org/10.1038/nrurol.2014.323
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.323
